WO2023171852A1 - Composition destinée à maintenir la stabilité de la sérotonine contenue dans le venin de vespa velutina - Google Patents

Composition destinée à maintenir la stabilité de la sérotonine contenue dans le venin de vespa velutina Download PDF

Info

Publication number
WO2023171852A1
WO2023171852A1 PCT/KR2022/006378 KR2022006378W WO2023171852A1 WO 2023171852 A1 WO2023171852 A1 WO 2023171852A1 KR 2022006378 W KR2022006378 W KR 2022006378W WO 2023171852 A1 WO2023171852 A1 WO 2023171852A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
black
venom
wasp venom
concentration
Prior art date
Application number
PCT/KR2022/006378
Other languages
English (en)
Korean (ko)
Inventor
김효정
박유진
정지운
김선건
이화진
Original Assignee
한국한의약진흥원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국한의약진흥원 filed Critical 한국한의약진흥원
Publication of WO2023171852A1 publication Critical patent/WO2023171852A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers

Definitions

  • the present invention relates to a composition for maintaining the stability of serotonin contained in black wasp venom.
  • a composition for maintaining stability that can suppress the decrease in the content of serotonin contained in black wasp venom in an aqueous solution and the same. It relates to an aqueous solution formulation of black wasp venom comprising:
  • Bee sting therapy also called bee sting or bee sting therapy, is a method of treating diseases by activating the body's immune function by injecting purified bee venom into acupuncture points.
  • the history of bengchim is very old, and it is currently established as an alternative medicine.
  • Bee needles are known to be particularly effective in treating inflammatory and painful diseases. They have excellent anti-inflammatory effects and have effects such as blood purification, hemolysis, nerve revitalization, sterilization, and tissue creation and destruction. It is known to have
  • melittin The main ingredient of bee venom extracted and purified from bees is melittin.
  • Melittin is a protein composed of 26 amino acids and makes up 40-50% of dried bee venom, and has been reported to be antibacterial, antiviral, induce hormone secretion, and stimulate enzyme secretion.
  • wasp venom Unlike bee venom, which has been actively used and studied in the treatment of diseases from ancient times to the present, wasp venom obtained from wasps is not properly used for therapeutic purposes and research is insufficient.
  • Wasp venom refers to a toxin used by wasps when looking for food or when an enemy invades their territory. It has a significant difference in composition from bee venom.
  • the components of wasp venom vary greatly depending on the type of wasp, and known ingredients include histamine, serotonin, dopamine, adrenaline, and acetylcholine.
  • the black-backed wasp ( Vespa velutina ) belongs to the Hymenoptera wasp family and is an exotic insect that was introduced into Korea from Southeast Asia in the early 2000s and is spreading nationwide.
  • Black-backed hornets are omnivorous insects that prey on a variety of insects, but they mainly hunt adult bees and prefer Western honey bees ( Apis mellifera ), causing great damage to the beekeeping industry.
  • the main ingredient with the highest content in black wasp venom is serotonin.
  • Patent Document 1 Republic of Korea Patent Publication No. 10-2019-0101980
  • Patent Document 2 Republic of Korea Patent Publication No. 10-2015-0137314
  • Patent Document 3 Republic of Korea Patent Publication No. 10-2018-0052128
  • Patent Document 4 Republic of Korea Patent Publication No. 10-2012-0029328
  • the purpose of the present invention is to provide a composition for maintaining stability that suppresses a decrease in the content of serotonin contained in black wasp venom in an aqueous solution.
  • the purpose of the present invention is to provide an aqueous solution formulation of black wasp venom with improved stability that can suppress the decrease in the content of serotonin contained in black wasp venom in an aqueous solution.
  • a composition for maintaining stability that inhibits the decrease in the content of serotonin contained in black wasp venom in an aqueous solution
  • composition comprising one or two or more stabilizers selected from Methyl ⁇ -Hydroxybenzoate, Cresol, and Chlorocresol as an active ingredient.
  • composition preferably in an aqueous solution, inhibits the content of serotonin contained in black wasp venom from being reduced by more than 15% based on HPLC peak area for at least 4 weeks.
  • Black wasp venom can be dissolved in the composition at a predetermined concentration and used.
  • black wasp venom is dissolved and used in the composition at a concentration of 2 to 8 mg/ml.
  • aqueous solution formulation containing one or two or more stabilizers selected from Methyl ⁇ -Hydroxybenzoate, Cresol, and Chlorocresol,
  • An aqueous solution formulation of black wasp venom is provided, which is characterized in that it inhibits the content of serotonin contained in the black wasp venom from being reduced by more than 15% for at least 4 weeks based on HPLC peak area.
  • the aqueous solution formulation of black wasp venom contains black wasp venom at a concentration of 2 to 8 mg/ml.
  • composition for maintaining stability of the present invention can significantly suppress the decrease in the content of serotonin contained in black wasp venom in an aqueous solution. After dissolving black wasp venom in the stability maintaining composition of the present invention, a decrease in serotonin content of more than 15% based on HPLC peak area can be suppressed for at least 4 weeks.
  • the stability-maintaining composition and the aqueous solution formulation of black wasp venom according to the present invention can be usefully applied to pharmaceutical compositions such as herbal medicine solutions and biological medicines, health foods, cosmetics, etc.
  • Figure 1 is an HPLC chromatogram showing the results of testing the stability of a composition in which black wasp venom was dissolved in sterilized distilled water and a stabilizer was added.
  • Figure 2 is an HPLC chromatogram showing the results of testing the stability of a composition in which black wasp venom was dissolved in sterilized saline and a stabilizer was added.
  • Figure 3 shows a comparison of the HPLC chromatographic changes over time of a composition in which black wasp venom was dissolved in sterilized distilled water without adding a stabilizer.
  • Figure 4 shows a comparison of the HPLC chromatographic changes over time of a composition in which black wasp venom was dissolved in sterilized saline without adding a stabilizer.
  • Figure 5 shows the results of confirming the change in serotonin content (%) over 4 weeks after preparing a composition in which black wasp venom was dissolved in sterilized distilled water or sterilized saline and a stabilizer was added.
  • Figure 6 shows the results of confirming the change in serotonin content (%) at 0 and 4 weeks after preparing a composition in which black wasp venom was dissolved in sterilized distilled water or sterilized saline and a stabilizer was added.
  • composition for maintaining stability provided by the present invention
  • a composition that inhibits the decrease in the content of serotonin contained in black wasp venom in an aqueous solution comprising: sterilized distilled water or sterilized physiological saline; and one or two or more stabilizers selected from Methyl ⁇ -Hydroxybenzoate, Cresol, and Chlorocresol as active ingredients.
  • black-backed wasp venom is defined as a toxin used by the black-backed wasp (Vespa velutina) when looking for food or when an enemy invades its territory, and contains serotonin as its main ingredient. It is obtained by separating and purifying the venom from the venom sac of the black-backed wasp.
  • stabilizer is defined as an additive for suppressing the decrease in serotonin content in black wasp venom.
  • the black wasp venom is produced by separating the venom from the venom sac of the black wasp. It can be purified and used, and to increase preservability, it can also be dried and powdered using a method such as freeze-drying.
  • the solvent forming the aqueous solution phase is sterilized distilled water or sterilized physiological saline solution.
  • the stabilizer one or two or more types selected from Methyl ⁇ -Hydroxybenzoate, Cresol, and Chlorocresol are used.
  • cresol and chlorocresol can be used more preferably because the increase in by-product peaks is relatively small.
  • Methyl paraoxybenzoate is preferably included in the composition at a concentration of 0.05-0.18% (w/v), and more preferably at a concentration of 0.1-0.18% (w/v).
  • Cresol is preferably included in the composition at a concentration of 0.15-0.4% (w/v), and more preferably at a concentration of 0.3-0.4% (w/v).
  • Chlorocresol is preferably included in the composition at a concentration of 0.1-0.2% (w/v), and more preferably at a concentration of 0.15-0.2% (w/v).
  • the serotonin content contained in black wasp venom is maintained at the highest level when sterilized saline solution is used as a solvent and chlorocresol at a concentration of 0.2% (w/v) is added.
  • Black wasp venom is used by dissolving it in the stability-maintaining composition at a desired concentration.
  • black wasp venom may be included in the composition at a concentration of 2 to 8 mg/ml, and is more preferably included at a concentration of 4 to 6 mg/ml. If black wasp venom is dissolved in a composition for maintaining stability to form an aqueous solution, the serotonin content can be stably maintained at a very high level even after 4 weeks of dissolution.
  • the content of serotonin in the black wasp venom contained in the composition for maintaining stability can be maintained at 85% or more for at least 4 weeks based on HPLC peak area, and more preferably at 90% or more.
  • Black-backed wasp venom Sterile distilled water or sterile saline solution; and one or two or more stabilizers selected from Methyl ⁇ -Hydroxybenzoate, Cresol, and Chlorocresol, and the content of serotonin contained in the black wasp venom is determined by HPLC. Suppress a decrease of more than 15% based on peak area for at least 4 weeks.
  • the stability-maintaining composition and the aqueous solution formulation of black wasp venom can be usefully applied to pharmaceutical compositions, health foods, cosmetics, etc. containing black wasp venom as an active ingredient.
  • An aqueous solution formulation of black wasp venom was prepared by dissolving black wasp venom powder in sterilized distilled water at a concentration of 5.0 mg/ml and adding methyl paraoxybenzoate at a concentration of 0.18% (w/v).
  • Black wasp venom powder was dissolved in sterilized distilled water at a concentration of 5.0 mg/ml and cresol was added at a concentration of 0.4% (w/v) to prepare an aqueous solution formulation of black wasp venom.
  • Black wasp venom powder was dissolved in sterilized distilled water at a concentration of 5.0 mg/ml and chlorocresol was added at a concentration of 0.2% (w/v) to prepare an aqueous solution formulation of black wasp venom.
  • Black wasp venom powder was dissolved in sterile saline solution (0.9% NaCl) at a concentration of 5.0 mg/ml and methyl paraoxybenzoate was added at a concentration of 0.18% (w/v) to prepare an aqueous solution formulation of black wasp venom.
  • Black wasp venom powder was dissolved in sterile saline solution (0.9% NaCl) at a concentration of 5.0 mg/ml and cresol was added at a concentration of 0.4% (w/v) to prepare an aqueous solution formulation of black wasp venom.
  • Black wasp venom powder was dissolved in sterile saline solution (0.9% NaCl) at a concentration of 5.0 mg/ml and chlorocresol was added at a concentration of 0.2% (w/v) to prepare an aqueous solution formulation of black wasp venom.
  • a composition for maintaining stability under experimental conditions was prepared using the following allowable additives.
  • the test subjects were first methyl paraoxybenzoate, A total of 9 types of additives were initially selected: propyl paraoxybenzoate, butyl paraoxybenzoate, chlorobutanol, benzalkonium chloride, benzethonium chloride, cresol, chlorocresol, and benzyl alcohol.
  • the first selected methyl paraoxybenzoate, propyl paraoxybenzoate, butyl paraoxybenzoate, chlorobutanol, benzalkonium chloride, benzethonium chloride, cresol, chlorocresol and benzyl alcohol were purchased from Sigma-aldrich (St. Louis, MO, USA). Purchased and used from .
  • Each additive was dissolved in sterilized distilled water or sterilized saline solution within the maximum concentration range permitted by the Ministry of Food and Drug Safety, then stored in a refrigerator, protected from light.
  • wasp venom powder extracted from black wasps in June 2020 and dried and powdered was used.
  • HPLC analysis was performed using a Waters ALLIANCE e2695 HPLC and 2998 PDA detector.
  • a YMC C 18 column (4.6 ⁇ 150 mm, 5 ⁇ m) was used as the stationary phase, and the column temperature was maintained at 30°C.
  • the sample temperature was maintained at 4°C to minimize the effect of temperature on the analysis sample.
  • the detection wavelength was set to 215 nm, which is the optimal detection wavelength for detection with the highest sensitivity by comparing chromatograms according to UV wavelengths of 190 to 400 nm.
  • HPLC analysis conditions including solvent gradient composition, are shown in Table 2 below.
  • the HPLC chromatogram resulting from testing the stability of a composition obtained by dissolving black wasp venom in sterilized distilled water and adding a stabilizer is shown in Figure 1, and shows the results of testing the stability of a composition obtained by dissolving black wasp venom in sterilized distilled water and adding a stabilizer.
  • the HPLC chromatogram resulting from the stability test is shown in Figure 2.
  • methyl paraoxybenzoate, cresol, and chlorocresol could be selected as stabilizers that inhibit the decrease of serotonin contained in black wasp venom.
  • cresol and chlorocresol were found to be more preferable as they showed a relatively small increase in by-product peaks ( Figures 1 and 2).
  • the stability-maintaining composition of the present invention and the aqueous solution formulation of black wasp venom containing the same described above are exemplary, and those skilled in the art will be able to make various modifications and other equivalent implementations thereof. You can see that an example is possible. Therefore, it will be well understood that the present invention is not limited to the forms mentioned in the description of the invention above.
  • the true technical protection scope of the present invention shall be determined by the technical spirit of the claims, and is understood to include all modifications, equivalents and substitutes within the spirit and scope of the present invention defined by the claims of the present invention. It has to be.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Insects & Arthropods (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Animal Husbandry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention se rapporte à une composition de maintien de stabilité apte à supprimer une diminution de la teneur en sérotonine contenue dans le venin de Vespa velutina en solution aqueuse et à une formulation aqueuse de venin de Vespa velutina la comprenant. La composition de maintien de stabilité de la présente invention comprend : de l'eau distillée stérile ou du sérum physiologique stérile ; et un ou plusieurs stabilisants choisis parmi le p-hydroxybenzoate de méthyle, le crésol, et le chlorocrésol en tant que principe actif, et peut supprimer une diminution de la teneur en sérotonine contenue dans le venin de Vespa velutina en solution aqueuse. La composition de maintien de stabilité et la formulation aqueuse de la présente invention peuvent être avantageusement appliquées à des compositions pharmaceutiques, telles que des pharmacopunctures, des produits biopharmaceutiques, etc., à des aliments diététiques, à des produits cosmétiques, etc.
PCT/KR2022/006378 2022-03-11 2022-05-04 Composition destinée à maintenir la stabilité de la sérotonine contenue dans le venin de vespa velutina WO2023171852A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020220030770A KR20230133595A (ko) 2022-03-11 2022-03-11 등검은말벌독에 함유된 세로토닌의 안정성을 유지하기 위한 조성물
KR10-2022-0030770 2022-03-11

Publications (1)

Publication Number Publication Date
WO2023171852A1 true WO2023171852A1 (fr) 2023-09-14

Family

ID=87935541

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/006378 WO2023171852A1 (fr) 2022-03-11 2022-05-04 Composition destinée à maintenir la stabilité de la sérotonine contenue dans le venin de vespa velutina

Country Status (2)

Country Link
KR (1) KR20230133595A (fr)
WO (1) WO2023171852A1 (fr)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000015224A1 (fr) * 1998-09-17 2000-03-23 Eli Lilly And Company Preparation a base de proteines
WO2011104557A1 (fr) * 2010-02-24 2011-09-01 Arecor Limited Formulations de protéines
KR20110139486A (ko) * 2010-06-23 2011-12-29 대한민국(농촌진흥청장) 꿀 및 봉독을 유효성분으로 함유하는 상처 치유용 피부외용제 조성물
KR20120029328A (ko) * 2010-09-16 2012-03-26 주식회사 엘지생명과학 높은 방부력을 제공하는 오일 주사 제형
KR20120120255A (ko) * 2009-12-22 2012-11-01 비씨엔 펩티드즈, 에스.에이. 국소적 안과용 펩티드 제제
KR20130098110A (ko) * 2012-02-27 2013-09-04 경희대학교 산학협력단 봉독-ｐｌａ2를 포함하는 이상 조절 ｔ 세포 활성 저하 관련 질환의 치료 또는 예방용 약학적 조성물
KR20160042120A (ko) * 2013-08-13 2016-04-18 상하이 베네마에 파머수티컬 코포레이션 안정한 인슐린 분비 촉진 펩티드의 하이드로 인젝션 약제학적 조성물
KR20190009589A (ko) * 2017-07-19 2019-01-29 대한민국(농촌진흥청장) 장수말벌의 일벌로부터 분리된 봉독을 함유하는 통풍의 예방 또는 치료용 조성물
WO2020190591A1 (fr) * 2019-03-15 2020-09-24 Eli Lilly And Company Formulations conservées

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150137314A (ko) 2014-05-29 2015-12-09 대한민국(농촌진흥청장) 봉독, 멜리틴 또는 아파민 성분을 포함하는 신장질환 예방 또는 치료용 약학조성물
CN108348465B (zh) 2015-09-17 2020-11-10 葛莱高托普有限公司 具有提高的稳定性的哺乳动物促卵泡激素组合物
PT3486233T (pt) 2017-03-27 2021-03-18 Fruithy Holdings Ltd Complexo pouco solúvel ou um seu solvato, composição farmacêutica e sua aplicação

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000015224A1 (fr) * 1998-09-17 2000-03-23 Eli Lilly And Company Preparation a base de proteines
KR20120120255A (ko) * 2009-12-22 2012-11-01 비씨엔 펩티드즈, 에스.에이. 국소적 안과용 펩티드 제제
WO2011104557A1 (fr) * 2010-02-24 2011-09-01 Arecor Limited Formulations de protéines
KR20110139486A (ko) * 2010-06-23 2011-12-29 대한민국(농촌진흥청장) 꿀 및 봉독을 유효성분으로 함유하는 상처 치유용 피부외용제 조성물
KR20120029328A (ko) * 2010-09-16 2012-03-26 주식회사 엘지생명과학 높은 방부력을 제공하는 오일 주사 제형
KR20130098110A (ko) * 2012-02-27 2013-09-04 경희대학교 산학협력단 봉독-ｐｌａ2를 포함하는 이상 조절 ｔ 세포 활성 저하 관련 질환의 치료 또는 예방용 약학적 조성물
KR20160042120A (ko) * 2013-08-13 2016-04-18 상하이 베네마에 파머수티컬 코포레이션 안정한 인슐린 분비 촉진 펩티드의 하이드로 인젝션 약제학적 조성물
KR20190009589A (ko) * 2017-07-19 2019-01-29 대한민국(농촌진흥청장) 장수말벌의 일벌로부터 분리된 봉독을 함유하는 통풍의 예방 또는 치료용 조성물
WO2020190591A1 (fr) * 2019-03-15 2020-09-24 Eli Lilly And Company Formulations conservées

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HAN SANG MI, KIM SE GUN, HONG IN PHYO, WOO SOON OK, JANG HYE RI, LEE KYUNG WOO: "Experimental studies of homogeneity and stability honeybee venom using ultra-high performance liquid chromatography", KOREAN JOURNAL OF VETERINARY SERVICE, vol. 39, no. 2, 30 June 2016 (2016-06-30), pages 81 - 86, XP093090238, ISSN: 1225-6552, DOI: 10.7853/kjvs.2016.39.2.81 *

Also Published As

Publication number Publication date
KR20230133595A (ko) 2023-09-19

Similar Documents

Publication Publication Date Title
WO2021040337A1 (fr) Composition à libération retardée de niclosamide et son utilisation antivirale
WO2011120281A1 (fr) Utilisation de l-oxiracétam dans la préparation de médicaments en vue de prévenir ou de traiter un dysfonctionnement cognitif
Monahan et al. Dose titration of moxidectin oral gel against gastrointestinal parasites of ponies
de Koning et al. Combination therapy for dendritic keratitis with acyclovir and α-interferon
WO2021049864A1 (fr) Composition permettant d'améliorer le syndrome de l'œil sec contenant un extrait d'aralia elata
WO2022124777A1 (fr) Complexe alloféron pour induire une activité immunitaire, ayant une stabilité à long terme
WO2023171852A1 (fr) Composition destinée à maintenir la stabilité de la sérotonine contenue dans le venin de vespa velutina
US7709534B2 (en) Method of treating strongyloides infections and medicaments therefor
WO2022114881A1 (fr) Composition pharmaceutique destinée à prévenir ou traiter une plaie ou une cicatrice, comprenant de la benzbromarone
DE2250032C3 (de) Arzneimittel auf der Basis von Lysinderivaten zur Bekämpfung der Leukopenie und zur Normalisierung der prozentualen Zusammensetzung des Leukocytenbildes
US20050171169A1 (en) Combination chemotherapy for helminth infections
KR101144715B1 (ko) 정자수 증가용 경구 투여제
KR20060127839A (ko) 펠라르고니엄 종으로부터 추출한 추출물의 용도
WO2012008697A2 (fr) Agent administré par voie orale pour l'augmentation de la quantité de sperme
WO2012046922A1 (fr) Nouvelle utilisation de peptides antimicrobiens dans la régénération de cellules de la peau
WO2017061663A1 (fr) Procédé de préparation de préparation ophtalmique contenant de la thymosine bêta-4
WO2020166773A1 (fr) Composition pour dissoudre des réserves lipidiques locales, comprenant un extrait médicamenteux brut en tant que principe actif
WO2023043219A1 (fr) Composition de gel pour la prévention ou le traitement de la dermatite atopique
WO2014185607A1 (fr) Composition pharmaceutique pour prévenir ou traiter la fibrose pulmonaire
WO2016032153A1 (fr) Procédé de préparation d'une solution aqueuse de minoxidil
WO2020235952A1 (fr) Composition pharmaceutique comprenant une fraction d'extrait de feuille de melissa officinalis
WO2010067953A2 (fr) Composition pharmaceutique pour la prévention ou le traitement de l'ostéoporose contenant des extraits de graine de vitis vinifera
WO2022177054A1 (fr) Composition pharmaceutique pour la prévention ou le traitement d'une infection par le coronavirus 2 responsable du syndrome respiratoire aigu sévère
WO2022255848A1 (fr) Nouveau peptide dérivé d'agkistrodon piscivorus piscivorus ou de naja mélanoleuca, et composition pour le traitement de la maladie de behcet ou de la polyarthrite rhumatoïde le comprenant
WO2016208926A1 (fr) Composition pharmaceutique comprenant un extrait d'artemisiae argyi folium dans l'isopropanol

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22931099

Country of ref document: EP

Kind code of ref document: A1